Medication Management for ADHD

Introduction to ADHD Treatment

ADHD is a condition with high heritability, and a comprehensive clinical interview is recommended to assess childhood history of symptoms, current symptoms across multiple settings, functional impairment in academic, occupational, and social domains, and family history of ADHD, as supported by the American Academy of Child and Adolescent Psychiatry 1
Executive function deficits should be assessed in working memory, inhibitory control, vigilance and attention, planning and organization, and reward regulation, as part of a comprehensive clinical interview, as supported by the American Academy of Child and Adolescent Psychiatry 1

The following medications are recommended for ADHD treatment:

Medication	Starting Dose	Target Dose
Atomoxetine (Strattera)	0.5 mg/kg/day	1.2 mg/kg/day
Bupropion	100-150 mg daily (sustained-release) or 37.5 mg every morning (increasing by 37.5 mg every 3 days)	150 mg twice daily
Guanfacine (Intuniv)	0.1 mg/kg once daily	-

Stimulant medications, such as methylphenidate, have larger effect sizes for core symptoms, including impulsivity, compared to non-stimulants like guanfacine, with a recommendation for stimulant medications as first-line treatment due to their superior efficacy, as supported by the American College of Pharmacology 1
Non-stimulant medications, such as atomoxetine, are recommended for patients with potential mood vulnerability, and for patients with substance use disorders due to lower abuse potential, as supported by the American Academy of Child and Adolescent Psychiatry 5, 1, 2, 3

The American Academy of Pediatrics notes that stimulant medications like methylphenidate can cause common side effects of stomach discomfort and decreased appetite 5
Methylphenidate provides a more rapid onset of action, within hours or days, compared to guanfacine, which takes 2-4 weeks, which may be a critical consideration when rapid symptom control is needed 1
Methylphenidate is more likely to cause decreased appetite, sleep disturbances, and potential growth effects, compared to guanfacine, which has a different side effect profile, as noted by the American College of Pharmacology 1
Stimulant medications, such as methylphenidate-based medications and amphetamine-based medications, can be used to treat ADHD, but may have side effects such as jaw clenching (bruxism), as noted by the American Academy of Child and Adolescent Psychiatry and the American College of Cardiology 6, 7

Atomoxetine is effective for ADHD symptoms, though with a slightly smaller effect size (0.7) compared to stimulants (1.0), according to the American Academy of Pediatrics 5
Atomoxetine may cause initial somnolence and gastrointestinal symptoms, and has a potential for hepatitis (rare) and increased suicidal thoughts (uncommon), as reported by the American Academy of Pediatrics 5
Guanfacine can be used as adjunctive therapy with stimulants to enhance efficacy or reduce stimulant side effects, and provides "around-the-clock" effects rather than time-limited coverage, as supported by the American College of Pharmacology 1
Alpha-2 agonists, such as clonidine or guanfacine, can be combined with stimulants for treating ADHD with comorbid tics, as recommended by the American Academy of Child and Adolescent Psychiatry 6
Administration of guanfacine in the evening is generally preferable due to somnolence as a common side effect, as noted by the American College of Pharmacology 1

Cognitive Behavioral Therapy (CBT) has been shown to be the most effective non-pharmacologic treatment for ADHD and can simultaneously address comorbid depression and anxiety, specifically targeting depression related to relationship issues, anxiety about future decisions, guilt regarding family relationships, and identity concerns, as supported by the American Academy of Child and Adolescent Psychiatry 2
A combined approach of non-stimulant medication with behavioral interventions offers the best chance for symptom improvement and functional gains in academic and social domains, as supported by the American Academy of Child and Adolescent Psychiatry 8, 5

Regular assessment of ADHD and anxiety symptoms using standardized scales, as well as monitoring of blood pressure, heart rate, and other side effects, is recommended at each visit, with schedule follow-up within 2-4 weeks after medication initiation, as recommended by the American Academy of Child and Adolescent Psychiatry 1, 3
Regular assessment for suicidal ideation is essential, particularly when initiating antidepressant therapy in young adults, as recommended by the American Academy of Child and Adolescent Psychiatry 9, 6

ADHD often co-exists with other psychiatric illnesses that may require simultaneous treatment, as noted by the American College of Obstetricians and Gynecologists 2
Limited safety data is available for ADHD medications during pregnancy and breastfeeding, though available data is largely reassuring, according to the American College of Obstetricians and Gynecologists 2
The American Academy of Child and Adolescent Psychiatry recommends avoiding the combination of sertraline with MAOIs due to the risk of serotonin syndrome 10
The American Academy of Child and Adolescent Psychiatry recommends avoiding the combination of Adderall (Amphetamine/Dextroamphetamine) or Strattera (Atomoxetine) with monoamine oxidase inhibitors due to the risk of serotonin syndrome 10